Leukemia Inhibitory Factor (LIF) is a polyfunctional cytokine with numerous regulatory effects in vivo and in vitro. In stem cell cultures it is the essential media supplement for the maintenance of pluripotency of embryonic and induced pluripotent stem cells. With regard to large scale cultures of these cells, LIF is needed in high quality and quantity and represents the major costs (90%) of the culture media. In this report, we describe a novel production and purification process for human LIF (hLIF) from recombinant E. coli cultures. hLIF was cloned into pET32b-trx and expressed as soluble protein in fusion with thioredoxin. After purification based on membrane adsorber technology, the fusion protein underwent cleavage by specific TEV protease. Released, soluble hLIF was subsequently purified by cation exchange chromatography and successfully tested for its biological activity using suspension cultures of murine embryonic and induced pluripotent stem cells. Our novel protocol for the production of recombinant hLIF is very suitable and effective for the production of low soluble proteins through expression in fusion with the solubilizing partner thioredoxin.
. In vivo, it regulates the survival of neurons [3] , [4] and acts as regulator of hematopoiesis [5] . In LIF -/-knock out mice it has been demonstrated that this cytokine is essential for blastocyst implantation [6] . Currently, LIF is in phase II clinical trial being developed as agent assisting the implantation of the embryo into the uterus in women who fail to become pregnant [7] .
Furthermore, LIF is able to maintain the pluripotency of murine embryonic stem cells [8] , [9] and is therefore extensively used in pluripotent stem cell culture. Due to their capacity of unlimited proliferation and ability to differentiate into cell types of all three germ layers, pluripotent stem cells are considered as highly interesting for both cell based therapies and the use in the pharmaceutical industry for drug screening and drug target identification. In order to facilitate the investigations of these cells for the mentioned applications, controlled, reproducible and scalable culture systems are needed to generate high amounts of undifferentiated cells [10] , [11] .
Besides the requirement of suitable culture systems cytokines such as LIF play a major role in large scale cultures of pluripotent stem cells. With commercially available LIF, we estimated this cytokine representing 90 % of the costs of the culture medium. To overcome this limitation it is desirable to have a source of highly purified and biological active LIF in large quantities.
Production and purification of LIF from recombinant E. coli have previously been reported. Gearing et al. [12] expressed murine and human LIF in a glutathione-Stransferase based fusion construct while Samal et al. [13] reported the expression of mature human LIF as insoluble inclusion bodies with subsequent refolding procedures. In this work we describe the development of a novel production and purification process for recombinant human LIF (hLIF). Mature 20 kDa hLIF contains six cysteine residues all being part of three disulfide bonds. In our approach, hLIF is expressed as soluble protein in fusion with thioredoxin. Bacterial thioredoxin has been found to act as a strong enhancer of the solubility of eukaryotic proteins [14] , [15] and is considered to actively promoting the disulfide bond formation of appropriate substrate proteins [16] . After purification of the soluble fusion protein, it was further processed by cleavage with highly active TEV protease that resulted in a complete digest of the fusion protein releasing soluble hLIF. Finally, bioactivity of the purified hLIF was tested using suspension cultures of pluripotent stem cells.
Materials and Methods

Construction of expression vector pET32b-trx-his-tev-hLIF
A hLIF cDNA encoding the mature 180 amino acid polypeptide was introduced downstream to the thioredoxin and His-tag coding sequence of pET32b-trx (Novagen).
Additionally, oligodeoxynucleotides (gag aat ctt tat ttt cag gga) encoding a TEV protease cleavage site were inserted directly 5´ to the hLIF cDNA replacing the origin thrombin cleavage site of the pET32b-trx vector.
Expression of recombinant hLIF in fusion with thioredoxin
For the expression of the fusion protein an E. coli BL21 (DE3) (Novagen) host strain was used. Expression cultures were inoculated with 2 % of over night grown preculture and performed in shaking flasks in TB medium at an agitation rate of 150 rpm. In order to increase the solubility of the fusion protein the cultivation temperature was set to 23°C. 
Purification of trx-his-tev-hLIF fusion protein
The overexpressed fusion protein was purified using a Sartobind IDA 75 membrane adsorber module (Sartorius-Stedim Biotech) [17] , [18] . In brief, after binding of Zn 2+ (0.5 M in 500 mM NaAc pH 4.5) to the membrane, soluble cell protein was loaded. The membrane was then washed with binding buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl) and washing buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl) before a pre-elution step was performed with 50 mM Tris-HCl pH 8.0 and 100 mM imidazole. A final elution of tightly bound protein was achieved with elution buffer containing 250 mM imidazole and 100 mM NaCl in 50 mM Tris-HCl, pH 7.5. Fractions containing the trx-his-tev-hLIF fusion protein were pooled and directly used for proteolytic cleavage. Protein concentration was determined by densitometry [19] using BSA as standard. For analysis, AlphaEaseFC Stand Alone Software was used.
1.4 Proteolytic cleavage of trx-his-tev-hLIF fusion protein
The purified fusion protein was cleaved by treating with recombinant TEV SH protease in a substrate to protease ratio of 10:1 (w/w). Cleavage was performed at 4°C in properly diluted 20 x TEV buffer (50 mM EDTA in 1 M Tris-HCl, pH 7.5) for 16 h.
Purification of hLIF after proteolytic cleavage
The released hLIF was purified from the protein mixture using a Sartobind S 75 membrane adsorber module (Sartorius-Stedim Biotech). After equilibration of the membrane with binding buffer (100 mM NaCl in 50 mM Tris-HCl, pH 7.0), the protein sample was loaded. The membrane was then washed with washing buffer before elution of the hLIF protein was performed with 1000 mM NaCl in 50 mM Tris-HCl, pH 7.25.
Protein concentration of hLIF containing fractions was determined by densitometry [19] using BSA as standard and analysing scanned SDS gels with AlphaEaseFC Stand Alone Software. To detect endotoxin levels, the hLIF protein solution was analysed by LAL Test 
Expression and purification of TEV SH protease
Recombinant TEV protease was expressed using TH24:TEV plasmid kindly provided by Helena Berglund [20] . The plasmid encodes a highly soluble mutant form of TEV protease referred as to TEV SH with a carboxy terminal His-tag (6 x His). Cultures of transformed E. coli Rosetta pLysS (Novagen) were carried out essentially as described previously [20] . After cell disruption and separation, TEV SH protease was purified using a Sartobind IDA 75 membrane adsorber module (Sartorius-Stedim Biotech) with immobilized Zn
2+
. After equilibration of the membrane with binding buffer (50 mM TrisHCl pH 8.0, 500 mM NaCl) the soluble protein fraction containing overexpressed TEV SH protease was loaded. The membrane was then washed with binding buffer before the target protein was eluted with a linear gradient from buffer A (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 100 mM imidazole) to buffer B (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 500 mM imidazole in 50 % glycerol). TEV SH protease containing fractions were pooled, aliquoted and stored at -20°C. Protein concentration was determined by densitometry [19] using BSA as standard. Scanned SDS gels were analysed with AlphaEaseFC Stand Alone Software. Overall production and purification process of hLIF Figure 2 gives an overview of the overall production process. For hLIF expression the transformed E. coli BL21 cells were cultivated in 100 ml TB medium in shaking flasks at a low temperature (23°C). Subsequent proteolytic cleavage of the purified fusion protein was carried out using TEV SH protease produced in recombinant E. coli as previously described [20] . The TEV SH protease was similarly purified via IMAC using membrane adsorber technology. Cleavage of the fusion protein was performed using a substrate to protease ratio of 1:10 (w/w). In Figure 3 .B, lane 2 the released His-tagged thioredoxin (14 kDa) and the hLIF protein (20 kDa) following proteolytic digest can be seen. A complete digest was achieved after 16 hours at 4 °C demonstrating the high efficiency of this protease. No further stabilizing agents such as glutathione were necessary to maintain the solubility of the released hLIF.
Biological testing of purified hLIF with murine ES and iPS cells
The last purification step consisted in the separation of hLIF from the protease and thioredoxin by cation exchange chromatography. The cleavage products were directly loaded on a membrane adsorber module functionalized with sulfonic acid. The elution fractions containing the purified hLIF were pooled. The quality of the final product can be seen in Figure 3 .B, lane 3. We estimated the purity being 95 % by SDS PAGE and silver staining. With this production and purification process 0.4 mg of hLIF per 100 ml bacterial culture broth could be obtained. The hLIF protein solution was essentially free of endotoxins (< 4 EU/µg) as determined by LAL test.
Biological testing of hLIF
The biological activity of the purified hLIF was proved using suspension cultures of murine embryonic and induced pluripotent stem cells. The activity of our material was compared to the activity of a commercially available LIF protein (ESGRO, Millipore).
Each cytokine was added to the culture media to a final concentration of 10 ng/ml respectively. As a negative control, cells were cultivated in the absence of LIF.
Maintenance of murine ES cells Brachyury in suspension cultures
Erlenmeyer flasks containing 25 ml medium (n=4) were inoculated with 2 x 10 With regard to growth and viability, the purified hLIF is comparable with commercially available ESGRO LIF. The maintenance of the cell's pluripotency however is another important aspect for the characterization of the purified cytokine.
SSEA-1 expression of Brachyury ES cells
Maintenance of pluripotency over long term suspension cultivation in the presence of the purified hLIF was evaluated by expression analysis of the pluripotency marker SSEA-1.
The expression level of the surface molecule was determined via flow cytometry using a monoclonal antibody labelled with FITC. In Figure 6 
Maintenance of iPS cells in suspension cultures
Additionally, the activity of LIF was tested using static suspension cultures of induced pluripotent stem (iPS) cells. As observed for the Brachyury ES cells, iPS cells cultured with the purified and control LIF throughout several passages did not show proliferation or viability differences (data not shown). Cell expression of both pluripotency markers Oct-3/4 and SSEA-1 was monitored simultaneously via multicolor flow cytometry.
Oct-3/4 expression was quantified according to GFP fluorescence, as the cells contain a GFP transgene under the control of the endogenous Oct-3/4 promoter (Reference U.
Martin). SSEA-1 surface expression was detected using a monoclonal antibody labelled with PE. The expression of both markers was simultaneously measured in a three colors experiment using propidium iodide for dead cell exclusion. In Figure This experiment demonstrated that the purified LIF can be used for suspension cultures of both murine ES and iPS cells.
Discussion
In this report we describe a novel production and purification process for human Leukemia Inhibitory Factor from recombinant E. coli cultures. We designed an expression vector where hLIF is expressed in fusion with a His-tagged thioredoxin. In between the two protein encoding sequences a cleavage site specifically recognized by TEV protease was inserted. When cultured at a low temperature (23°C) the E. coli cells 
